What a Certificate of Analysis Can and Cannot Tell You About Peptide Purity

Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the standard pharmacopeial method for determining chemical purity under USP Chapter <621>. The instrument dissolves a powder sample and pumps it under extreme hydraulic pressure (often 2,000 to 15,000 psi) through a silica column coated with hydrocarbon chains (such as C18). Different molecules exit the column at different retention times, passing an ultraviolet (UV) absorbance detector.

The resulting chromatogram displays 'peaks' representing detected substances. If a report states '99.1% purity,' this means the primary peptide peak accounts for 99.1% of the total UV absorbance area under the curve. Crucially, HPLC purity is relative: it reflects the ratio of the target peptide to other UV-absorbing chemical fragments, but does not identify non-absorbing fillers, excipients (such as mannitol bulking agents), or moisture content.

While HPLC confirms how cleanly a compound separates, Mass Spectrometry (MS) verifies what the molecule actually is. Using Electrospray Ionization (ESI) or Matrix-Assisted Laser Desorption/Ionization (MALDI), the spectrometer ionizes peptide molecules and measures their mass-to-charge ratio (m/z).

A mass spectrum confirms whether the observed molecular weight matches the theoretical calculated mass of the peptide sequence (for example, BPC-157 at 1419.5 Da or Tirzepatide at 4813.5 Da). However, standard mass spectrometry cannot detect stereochemical inversions (D- versus L-amino acids) or subtle sequence scrambling where identical amino acid residues swap positions without changing total mass.

Reviewing a COA requires understanding several critical blind spots:

• No Automatic Sterility Guarantee: An HPLC/MS purity report only measures chemical purity; it does not indicate microbial sterility unless a dedicated 14-day USP <71> membrane filtration incubation test is explicitly reported.
• Zero Post-Puncture Insight: A COA reflects the stability of dry lyophilized powder on the day of testing in an analytical lab. It cannot predict degradation rates after reconstitution with bacteriostatic water.
• Vial-to-Vial Inconsistency: Without an unbroken pharmaceutical chain of custody, a single batch report cannot guarantee that every individual customer vial contains identical nominal mass.
• Bulking Agents versus Net Content: Lyophilized vials contain bulking agents (typically 10 mg to 50 mg of mannitol) to form a stable lyophilized cake. HPLC reports do not measure mannitol mass.

A frequent question in research forums is whether peptide purity can be evaluated at home using test strips, color reagents, or portable meters. Scientifically, at-home purity testing is impossible.

Quantifying peptide purity requires resolving molecular chains differing by a single amino acid deletion (e.g., a 38-amino-acid truncated impurity versus a 39-amino-acid target). This separation requires high-pressure liquid pumps, specialized analytical columns, wavelength-calibrated UV detectors, and ultra-pure mobile phase solvents. Simple chemical drop tests or test strips only react to broad organic functional groups (such as peptide bonds or amines), turning colors in the presence of almost any protein or amino acid without distinguishing between target compound, degradation fragments, or contaminants. Reliable verification requires certified analytical chromatography.